2026年8月26日 世界协调时下午4:48 / 路透社
2014年8月20日在卢布尔雅那拍摄的资料图片中，药品片剂和胶囊被摆成美元符号的形状。拍摄于8月20日。REUTERS/Srdjan Zivulovic 购买授权链接，将在新标签页打开
8月26日（路透社）——彭博新闻周三援引知情人士消息报道，美国总统唐纳德·特朗普政府计划于周一宣布与中型生物技术公司达成新一轮药品定价协议。
根据报道，这些公司将同意向州医疗补助计划提供门诊药品折扣，使得各州支付的价格与这些公司在国外的收费标准保持一致。
路透社每日简报新闻简报可为您提供开启一天所需的全部新闻。点击此处订阅。
广告 · 继续向下滚动
报道未提及哪些制药商将同意降价。路透社无法立即核实该报道。
截至目前，特朗普政府已与17家制药公司达成自愿协议，为政府医疗补助计划和自费患者降低药品价格，其中包括辉瑞（PFE.N，将在新标签页打开）、礼来（LLY.N，将在新标签页打开）和安进（AMGN.O，将在新标签页打开）。
目前美国患者为处方药支付的价格遥遥领先，往往几乎是其他发达国家的三倍。特朗普一直在施压制药商将药品价格降至其他地区患者支付的水平。
广告 · 继续向下滚动
作为自愿协议的一部分，特朗普还争取到了GLP-1药物的降价，扩大了医疗保险对肥胖治疗的覆盖范围。
今年5月，政府表示，这些定价协议预计将在未来10年内为联邦和各州带来643亿美元的储蓄。
blob:https://www.reuters.com/bd681607-4ea6-4820-8114-fe6013b70b76
由班加罗尔的加尔吉·古普塔和克里斯蒂·桑托什报道，富兰克林·保罗和乔纳森·阿南达编辑
White House to announce new drug pricing deals with biotechs, Bloomberg News reports
August 26, 2026 4:48 PM UTC / Reuters
Pharmaceutical tablets and capsules are arranged in the shape of a U.S. dollar sign on a table in this picture illustration taken in Ljubljana August 20, 2014. Picture taken August 20. REUTERS/Srdjan Zivulovic Purchase Licensing Rights, opens new tab
Aug 26 (Reuters) – U.S. President Donald Trump’s administration is planning to announce a new round of drug-pricing agreements with midsize biotech companies on Monday, Bloomberg News reported on Wednesday, citing people familiar with the matter.
The companies will agree to provide discounts on outpatient drugs to state Medicaid programs such that the prices states pay align with what the companies charge in foreign countries, according to the report.
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
Advertisement · Scroll to continue
The report did not mention which drugmakers would be agreeing to the price reductions. Reuters could not immediately verify the report.
To date, the Trump administration has reached voluntary agreements with 17 pharmaceutical companies to slash medicine prices for the government’s Medicaid program and for cash payers, including Pfizer (PFE.N), opens new tab, Eli Lilly (LLY.N), opens new tab and Amgen (AMGN.O), opens new tab.
U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than other developed nations. Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.
Advertisement · Scroll to continue
As part of the voluntary agreements, Trump has also secured price reductions for GLP-1 drugs, expanding Medicare coverage for obesity treatments.
In May, the administration said the pricing deals are expected to generate $64.3 billion in federal and state savings in the next 10 years.
blob:https://www.reuters.com/bd681607-4ea6-4820-8114-fe6013b70b76
Reporting by Gargi Gupta and Christy Santhosh in Bengaluru, Editing by Franklin Paul and Jonathan Ananda
发表回复